- Home
- Publications
- Publication Search
- Publication Details
Title
Combination Therapies for Nonalcoholic Fatty Liver Disease
Authors
Keywords
-
Journal
Journal of Personalized Medicine
Volume 12, Issue 7, Pages 1166
Publisher
MDPI AG
Online
2022-07-18
DOI
10.3390/jpm12071166
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combined EXENatide and DApagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycemic control in patients with type 2 diabetes mellitus treated with metformin – EXENDA , a 24 week, prospective, randomized, placebo‐controlled pilot trial
- (2021) Jürgen Harreiter et al. DIABETES OBESITY & METABOLISM
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- (2021) Suetonia C Palmer et al. BMJ-British Medical Journal
- Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis (nash) in five european countries in 2018: A cost‐of‐illness analysis
- (2021) Jörn M. Schattenberg et al. LIVER INTERNATIONAL
- Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations
- (2021) Stergios A. Polyzos et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
- (2021) Evangelia S. Makri et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study
- (2021) Eu Jeong Ku et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Nonalcoholic fatty liver disease: lifestyle and quality of life
- (2021) Ilias Vachliotis et al. Hormones-International Journal of Endocrinology and Metabolism
- Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
- (2020) Rod S. Taylor et al. GASTROENTEROLOGY
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Complications, morbidity and mortality of nonalcoholic fatty liver disease
- (2020) Alessandro Mantovani et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
- (2020) Evangelia Makri et al. ARCHIVES OF MEDICAL RESEARCH
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
- (2019) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease
- (2019) Stefania Grimaudo et al. Clinical Gastroenterology and Hepatology
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis
- (2019) Vasiliki Venetsanaki et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients
- (2019) Alessandro Federico et al. Oxidative Medicine and Cellular Longevity
- Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
- (2019) Amalia Gastaldelli et al. DIABETES OBESITY & METABOLISM
- Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
- (2019) Julia Wattacheril GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?
- (2018) Stergios A. Polyzos et al. HEPATOLOGY
- Genetics and epigenetics of NAFLD and NASH: Clinical impact
- (2018) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Endoplasmic Reticulum stress signaling and the pathogenesis of Non-Alcoholic Fatty Liver Disease
- (2018) Cynthia Lebeaupin et al. JOURNAL OF HEPATOLOGY
- Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
- (2018) Thomas Jensen et al. JOURNAL OF HEPATOLOGY
- GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
- (2018) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study
- (2017) Kathryn Stiede et al. HEPATOLOGY
- Pathology of non-alcoholic fatty liver disease
- (2017) Pierre Bedossa LIVER INTERNATIONAL
- The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement
- (2017) Vasilios G. Athyros et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Emerging and future therapies for nonalcoholic steatohepatitis in adults
- (2016) Gesthimani Mintziori et al. EXPERT OPINION ON PHARMACOTHERAPY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Nonalcoholic fatty future disease
- (2016) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
- (2016) Manoela Mota et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Epidemiology and natural history of non-alcoholic fatty liver disease
- (2016) Yousef Fazel et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Adipokines in nonalcoholic fatty liver disease
- (2016) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review
- (2016) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
- (2016) Elena Buzzetti et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
- (2016) Evangelia Makri et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Non-alcoholic fatty liver and the gut microbiota
- (2016) Stavros Bashiardes et al. Molecular Metabolism
- Effect of Insulin Versus Triple Oral Therapy on the Progression of Hepatic Steatosis in Type 2 Diabetes
- (2016) Ildiko Lingvay et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial
- (2016) Claudia Della Corte et al. PLoS One
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- Genetic and epigenetic mechanisms of NASH
- (2015) Mohammed Eslam et al. Hepatology International
- Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis
- (2015) Laura J Carbone et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- An update on the validity of irisin assays and the link between irisin and hepatic metabolism
- (2015) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Nonalcoholic fatty liver disease and statins
- (2015) Konstantinos Tziomalos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Resistant Nonalcoholic Fatty Liver Disease Amelioration With Rosuvastatin and Pioglitazone Combination Therapy in a Patient With Metabolic Syndrome
- (2014) Daniel M. Riche et al. ANNALS OF PHARMACOTHERAPY
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
- (2014) Ning Shao et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review
- (2013) Zun Xiang et al. BMC GASTROENTEROLOGY
- Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial
- (2012) Carmela Loguercio et al. FREE RADICAL BIOLOGY AND MEDICINE
- Nonalcoholic Fatty Liver Disease
- (2012) Stergios A. Polyzos et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Helicobacter pylori infection in patients with nonalcoholic fatty liver disease
- (2012) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
- (2011) E. Boettcher et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease
- (2011) S. A. Polyzos et al. CURRENT MOLECULAR MEDICINE
- Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes
- (2011) P. K. Shah et al. DIABETES OBESITY & METABOLISM
- Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial
- (2011) Dawn M. Torres et al. HEPATOLOGY
- Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease
- (2011) Stergios A Polyzos et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes
- (2011) Padma Sathyanarayana et al. Obesity
- Human Fatty Liver Disease: Old Questions and New Insights
- (2011) J. C. Cohen et al. SCIENCE
- Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results
- (2011) Florence Pietu et al. Clinics and Research in Hepatology and Gastroenterology
- Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial
- (2010) Temitope Foster et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose Diet
- (2010) Tsutomu Wada et al. ENDOCRINOLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Peroxisome Proliferator-Activated Receptor γ Coactivator-1 β in the Pathogenesis of Fructose-Induced Insulin Resistance
- (2009) Yoshio Nagai et al. Cell Metabolism
- Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines
- (2009) Stergios Polyzos et al. CURRENT MOLECULAR MEDICINE
- The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease
- (2009) Stergios A. Polyzos et al. DIABETES OBESITY & METABOLISM
- Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease
- (2009) Ziya Omer et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): A randomized controlled pilot trial
- (2009) N. Sturm et al. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
- Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
- (2009) Vlad Ratziu et al. HEPATOLOGY
- Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
- (2009) Philippe Lefebvre et al. PHYSIOLOGICAL REVIEWS
- Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal
- (2009) Naim Alkhouri et al. Expert Review of Gastroenterology & Hepatology
- Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial
- (2008) Valerio Nobili et al. HEPATOLOGY
- Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial
- (2008) Stephen A. Harrison et al. HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More